Egypt, Norway's Scatec explore deeper cooperation in renewable energy    Emergency summit in Doha as Gaza toll rises, Israel targets Qatar    Egypt's EDA, Korean pharma firms explore investment opportunities    CBE, banks to launch card tokenization on Android mobile apps    CIB completes EGP 2.3bn securitization for GlobalCorp in seventh issuance    Ex-IDF chief says Gaza war casualties exceed 200,000, legal advice 'never a constraint'    Right-wing figures blame 'the Left' for Kirk killing, some urge ban on Democratic Party    Egypt's FM heads to Doha for talks on Israel escalation    Egypt's Sisi ratifies €103.5m financial cooperation deal with Germany    Egypt strengthens inter-ministerial cooperation to upgrade healthcare sector    Egyptian government charts new policies to advance human development    Egypt advances plans to upgrade historic Cairo with Azbakeya, Ataba projects    Egyptian pound ends week lower against US dollar – CBE    Egypt expresses condolences to Sudan after deadly Darfur landslides    Egypt hosts G20 meeting for 1st time outside member states    Lebanese Prime Minister visits Egypt's Grand Egyptian Museum    Egypt to tighten waste rules, cut rice straw fees to curb pollution    Egypt seeks Indian expertise to boost pharmaceutical industry    Egypt prepares unified stance ahead of COP30 in Brazil    Egypt recovers collection of ancient artefacts from Netherlands    Egypt harvests 315,000 cubic metres of rainwater in Sinai as part of flash flood protection measures    Egyptian, Ugandan Presidents open business forum to boost trade    Al-Sisi says any party thinking Egypt will neglect water rights is 'completely mistaken'    Egypt's Sisi, Uganda's Museveni discuss boosting ties    Egypt, Huawei explore healthcare digital transformation cooperation    Foreign, housing ministers discuss Egypt's role in African development push    Greco-Roman rock-cut tombs unearthed in Egypt's Aswan    Egypt reveals heritage e-training portal    Sisi launches new support initiative for families of war, terrorism victims    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Debate heats up over using an anti-malaria drug for COVID-19
Published in Ahram Online on 06 - 04 - 2020

President Donald Trump and members of his administration are growing emphatic in promoting an anti-malaria drug not yet officially approved for fighting COVID-19, even though scientists say more testing is needed before it's proven safe and effective against the virus
Trump trade adviser Peter Navarro promoted the drug, hydroxychloroquine, in television interviews Monday, a day after Trump publicly put his faith in the drug to lessen the toll of the coronavirus pandemic.
"What do I know, I'm not a doctor," Trump told reporters Sunday. "But I have common sense."
The administration's public backing of the drug comes after a heated Situation Room meeting of the White House's coronavirus task force on Saturday, in which Navarro challenged the top U.S. infectious disease expert, Dr. Anthony Fauci, over his concerns about recommending the drug based only on unscientific anecdotal evidence.
Navarro, who has no formal medical training, erupted at Fauci, raising his voice and claiming that the reports of studies he collected were enough to recommend the drug widely, according to a person familiar with the exchange who spoke on the condition of anonymity to describe the Situation Room blow-up.
Fauci has repeatedly said that current studies provide only anecdotal findings that the drug works. Navarro told CNN on Monday: "I would have two words for you: 'second opinion.'"
Hydroxychloroquine is officially approved for treating malaria, rheumatoid arthritis and lupus, but not COVID-19. Small, preliminary studies have suggested it might help prevent the new coronavirus from entering cells and possibly help patients clear the virus sooner. But those have shown mixed results.
Doctors are already prescribing the malaria drug to patients with COVID-19, a practice known as off-label prescribing. Research studies are now beginning to test if the drugs truly help COVID-19 patients, and the Food and Drug Administration has allowed the drugs into the national stockpile as an option for doctors to consider for patients who cannot get into one of the studies.
But the drug has major potential side effects, especially for the heart, and Fauci has said more testing is needed before it's clear that the drug works against the virus and is safe for use.
Navarro told Fox News Channel's "Fox & Friends" that doctors in New York hospitals are already giving out the drug to COVID-19 patients and that health care workers are taking it in hopes of being protected from infection. And while he acknowledged the Saturday debate with Fauci, he said the focus was on whether the administration should take 29 million doses of the drug in Federal Emergency Management Agency warehouses and send them to hard-hit cities.
"The media is trying to blow it up as a big big debate, but I can tell you that within the room the decision was a sound one, and it was unanimous," Navarro said.
Asked about his credentials for pushing the drug, Navarro cited his doctorate in social science.
"In the fog of war, we might take more risks than we otherwise would. And, given the track record of the drug over many many years in treating malaria that there are side effects but it's been used a lot in lesser doses, the decisions's been made by many doctors to prescribe it," Navarro said. "If it saves lives, that's a beautiful thing ... I think history will judge who's right on this debate. I'd bet on President Trump's intuition on this one."
Trump has been enthusiastically supporting the drug. He announced Sunday that his administration has amassed 29 million doses for distribution to areas of the country hard-hit by the coronavirus.
"There's a study out there that says people that have lupus haven't been catching this virus," Trump said. "You know, maybe it's true, maybe it's not. ... There's also other studies ... that the malaria countries ... have very little of this virus."
Trump said he would likely take the drug. "I may take it. OK? I may take it. And I'll have to ask my doctors about that, but I may take it."
Administration officials say Trump's embrace of the drug stems from his desire to provide "hope" for the American people as the death toll mounts and he looks to avoid political consequences from the outbreak.
Some limited studies have been conducted on the use of hydroxychloroquine and antibiotic azithromycin in concert to treat COVID-19, but they have not included critical control groups that scientists use to validate the conclusions.
A series of 11 patients in France found that an antibiotic-malaria drug combo did not improve how fast patients cleared the virus or their symptoms. Researchers in China reported that cough, pneumonia and fever seemed to improve sooner among 31 patients given hydroxychloroquine compared with 31 others who did not get the drug, but fewer people in the comparison group had cough or fevers to start with.
At least one other world leader has followed on Trump's claims to promote the use of the drugs.
Brazil's President Jair Bolsonaro has repeatedly touted the benefits of hydroxychloroquine and azithromycin. He said he heard reports of 100% effectiveness when administered in the correct dosages, zeroed tariffs for import of the drugs and has announced ramped-up chloroquine production.
On Sunday, he shared a video on social media of Trump's personal attorney Rudy Giuliani interviewing a doctor who claimed he has successfully treated hundreds of coronavirus patients with the drugs.
Brazil's health minister Luiz Henrique Mandetta, who has led the nation's virus response and endorsed broad isolation measures, said on April 3 that initial tests of chloroquine's efficacy remain "fragile." Still, he announced the government would broaden criteria for the drug's use in "grave" cases. Previously, it had only authorized its use in "critical" cases.
Fringe news sites, pro-Trump social media users and pundits have pushed hydroxychloroquine as a miracle drug for weeks. Social media platforms have taken down references from conservative personalities and politicians who claim hydroxychloroquine is an infallible method for treating COVID-19 patients.
Last week, Twitter and Facebook took the unprecedented step of removing video posts from Bolsonaro. He stated in one that hydroxychloroquine was "working in all places" to treat coronavirus.
Twitter also removed a tweet from Giuliani asserting that the drug is "100 percent effective" in treating coronavirus. Giuliani has since made the claim on cable news network Fox News.
For most people, the virus causes mild or moderate symptoms, such as fever and cough that clear up in two to three weeks. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia, and death.


Clic here to read the story from its source.